Pharmacological inhibition of IRE1α endonuclease function selectively blocks cross-presentation of tumor-associated antigen to major histocompatibility complex class I pathway without impairing presentation of tumor antigens to major histocompatibility complex class II, leading to inhibition of CD8+ T-cell priming (119). Here, CD8A is linked to neoplasm.